Form 4: Vaccinex CEO Maurice Zauderer Reports Changes in Beneficial Ownership

Vaccinex CEO Maurice Zauderer reports transactions involving common stock and derivative securities, including stock options and warrants.

Summary

• Maurice Zauderer, the CEO of Vaccinex, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report includes transactions involving common stock, stock options, and warrants.
• Some shares are held directly, while others are held indirectly through trusts and Vaccinex (Rochester), L.L.C.
• The filing reflects a 1-for-14 reverse stock split that was effected on February 19, 2024.
• Zauderer disclaims beneficial ownership of shares held by Jeremy C. Zauderer Trust, Jordan M. Zauderer Trust, and Vaccinex (Rochester), L.L.C. except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine filing of insider transactions. The disposal of shares is slightly negative, but the granting of options is slightly positive. The reverse stock split is a concern.

Positives

• The granting of new stock options to the CEO could be seen as an incentive to improve company performance.

Negatives

• The disposal of 1,580 shares of common stock by the CEO could be interpreted negatively by some investors.

Risks

• The reverse stock split implemented on February 19, 2024, could indicate financial difficulties or an attempt to maintain listing requirements.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors monitor these filings to gain insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Comparing the CEO's holdings and transactions to those of executives at similar-sized biotech companies can provide context.
• For example, CEOs at companies like Celldex Therapeutics or Gritstone Bio also regularly report Form 4 transactions.
• Analyzing the types of equity compensation (stock options vs. restricted stock) and the vesting schedules can reveal how Vaccinex's practices align with industry norms.

Stakeholder Impact

• The reported transactions may influence investor sentiment and potentially affect the stock price.
• Employees holding stock options may be affected by the vesting schedules and exercise prices.

Key Dates

Keywords

Vaccinex, Maurice Zauderer, Form 4, Beneficial Ownership, Stock Options, Warrants, Reverse Stock Split, Securities, VCNX